Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab Higher Dose in Relapsing Multiple Sclerosis
NCT04544436Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoint: Time to Onset of 12-week Composite Confirmed Disability Progression up to 4 years. Started Nov 2020; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04544436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544436.